Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Terminated 2Completed 2Active not recruiting 2

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1Genitourinary 1

Conditions

Small Cell Lung Carcinoma 1Prostatic Neoplasms 1Neoplasm Metastasis 1

Interventions

Cyclophosphamide 222pembrolizumab 201Carboplatin 173Cisplatin 168Gemcitabine 167Paclitaxel 155Docetaxel 140Bevacizumab 138Rituximab 137Radiotherapy 137Nivolumab 126Dexamethasone 126Capecitabine 103fludarabine 102Pemetrexed 92fludarabine phosphate 91Fluorouracil 91Doxorubicin 85Oxaliplatin 79Etoposide 77Cytarabine 77Bortezomib 76Erlotinib Hydrochloride 74Leucovorin 72Filgrastim 68Lenalidomide 67Calcium Dobesilate 66Irinotecan 65atezolizumab 63Radiation 61

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Has results × navitoclax × Clear all
NCT03366103 2023-10-17

Navitoclax and Vistusertib in Treating Patients With Relapsed Small Cell Lung Cancer and Other Solid Tumors

National Cancer Institute (NCI)

Phase 1/2 Terminated
15 enrolled 14 charts
Thoracic

Neoplasm Metastasis, Small Cell Lung Carcinoma

NCT01828476 2017-05-04

Navitoclax and Abiraterone Acetate With or Without Hydroxychloroquine in Treating Patients With Progressive Metastatic Castrate Refractory Prostate Cancer

Rutgers, The State University of New Jersey

Phase 2 Terminated
13 enrolled 5 charts
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡